Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants

Kairos Pharma, LTD.

Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
Each Pre-Funded Unit includes a pre-funded warrant (exercise $0.001) and 1.5 common warrants (exercise $1.40).
Amended agreement requires shareholder approval before issuing >19.99% of common stock.
Placement agents Boustead and D. Boral receive 8% cash commission plus warrants for 175,000 shares at $1.40.
Offering closed on January 16, 2025; securities sold under Section 4(a)(2) and Rule 506(b).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.